<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01125514</url>
  </required_header>
  <id_info>
    <org_study_id>CSPP100A2255</org_study_id>
    <nct_id>NCT01125514</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure</brief_title>
  <official_title>A Single-blind, Multiple Dose, Placebo-controlled, Double Dummy Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study assessed the interaction between single and multiple doses of aliskiren (150 mg
      and 300 mg) and furosemide (60 mg) in patients with heart failure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diuretic Efficacy Index 1 for Sodium Excretion</measure>
    <time_frame>0 to 4 hours</time_frame>
    <description>Efficacy of furosemide for sodium excretion (efficacy index 1) was defined by dividing urinary sodium excretion by the urinary excretion of furosemide. Diuretic index 1 for sodium was calculated for the for the total 0 to 4 hour urine collection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diuretic Efficacy Index 1 for Sodium Excretion</measure>
    <time_frame>0 to 24 hours</time_frame>
    <description>Efficacy of furosemide for sodium excretion (efficacy index 1) was defined by dividing urinary sodium excretion by the urinary excretion of furosemide. Diuretic index 1 for sodium was calculated for the for the total 0 to 24 hour urine collection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diuretic Efficacy Index 2 for Water Excretion</measure>
    <time_frame>0 to 4 hours</time_frame>
    <description>Efficacy of furosemide for water excretion (efficacy index 2) was defined by dividing urine volume by the urinary excretion of furosemide.Diuretic index 2 for water was calculated for the 0 to 4 hour fraction urine collection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diuretic Efficacy Index 2 for Water Excretion</measure>
    <time_frame>0 to 24 hours</time_frame>
    <description>Efficacy of furosemide for water excretion (efficacy index 2) was defined by dividing urine volume by the urinary excretion of furosemide.Diuretic index 2 for water was calculated for the 0 to 4 hour fraction and for the total 0 to 24 hour urine collection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of Furosemide: Area Under the Plasma Concentration-time Curve (AUC)</measure>
    <time_frame>pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>Pharmacokinetic (PK) parameters were determined from the plasma concentration time profile of furosemide using a non-compartmental method:
AUCtau: Area under the plasma concentration-time curve from time zero to the end of the dosing interval
AUC (0-24): Area under the plasma concentration-time curve from time zero to 24 hours
AUClast: Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration. AUClast was calculated as the sum of linear trapezoids using non-compartmental analysis.
AUCinf: Area under the plasma concentration-time curve from time zero to infinity. AUCinf was calculated by adding AUClast and the value obtained from dividing the last measurable plasma concentration by λz, where λz was determined from automated linear regression of the last three time points with non-zero concentrations in the terminal phase of the log-transformed concentration-time profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of Furosemide: Observed Maximum Plasma Concentration Following Drug Administration at Steady State (Cmax, ss)</measure>
    <time_frame>pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>Cmax,ss was directly determined from the raw plasma concentration-time data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of Furosemide: Time to Reach the Maximum Concentration After Drug Administration (Tmax)</measure>
    <time_frame>pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>Tmax was directly determined from the raw plasma concentration-time data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of Furosemide: Average Steady State Plasma Concentration During Multiple Dosing (Cav,ss)</measure>
    <time_frame>pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
    <description>The average steady-state drug concentration in the plasma, blood, serum, or other body fluids during multiple dosing [amount x volume-1]. This was estimated as AUCτ/τ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of Furosemide: Lowest Plasma Concentration Observed During a Dosing Interval at Steady State (Cmin, ss)</measure>
    <time_frame>pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 24 hours post dose</time_frame>
    <description>The minimum observed steady-state drug concentration in the plasma, blood, serum, or other body fluids at the end of the dosing interval during multiple dosing [amount x volume-1]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Pharmacokinetics (PK) of Furosemide: Amount of Drug Excreted Into the Urine From Time Zero to 24 Hours After Administration (Ae0-24)</measure>
    <time_frame>0 to 4, 4 to 8, 8 to 12 and 12 to 24 hours post dose</time_frame>
    <description>The area under the plasma (or serum or blood) concentration-time curve from time zero to 24 h [mass × time × volume-1]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Pharmacokinetics (PK) of Furosemide: Renal Clearance (CLR)</measure>
    <time_frame>0 to 4, 4 to 8, 8 to 12 and 12 to 24 hours post dose</time_frame>
    <description>The renal clearance of drug [volume x time-1]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine Clearance</measure>
    <time_frame>0 to 4, 4 to 8, 8 to 12 and 12 to 24 hours post dose</time_frame>
    <description>Creatinine clearance= (Urine creatinine/Serum creatinine) x (Urine volume/(24*60)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Sodium and Potassium Excretion Per Treatment at 4 Hours Postdose</measure>
    <time_frame>4 hours postdose</time_frame>
    <description>Urine was collected 4 hours postdose in all treatment groups for sodium and potassium analysis. Each patient was required to void their bladder before drug administration and at the end 4 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Sodium and Potassium Excretion Per Treatment at 8 Hours Postdose</measure>
    <time_frame>8 hours postdose</time_frame>
    <description>Urine was collected 8 hours postdose in all treatment groups for sodium and potassium analysis. Each patient was required to void their bladder before drug administration and at the end 8 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Sodium and Potassium Excretion Per Treatment at 12 Hours Postdose</measure>
    <time_frame>12 hours postdose</time_frame>
    <description>Urine was collected 12 hours postdose in all treatment groups for sodium and potassium analysis. Each patient was required to void their bladder before drug administration and at the end 12 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Sodium and Potassium Excretion Per Treatment at 24 Hours Postdose</measure>
    <time_frame>24 hours postdose</time_frame>
    <description>Urine was collected 24 hours postdose in all treatment groups for sodium and potassium analysis. Each patient was required to void their bladder before drug administration and at the end 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Sitting Systolic Blood Pressure (msSBP)and Mean Sitting Diastolic Blood Pressure (msDBP)</measure>
    <time_frame>0.5 hour pre-dose, 0.5, 1, 2, 4, 8, 12 and 24 hours post dose.</time_frame>
    <description>Sitting blood pressure was measured three times at 1 to 2-minute intervals. The mean of the three sitting blood pressure measurements was used as the average of the sitting office blood pressure. The msSBP and msDBP data were analyzed using a mixed effect model with fixed effects from treatment and treatment*time; random effect from patients and predose as covariate.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Furosemide 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment period 1 (Day 1 to Day 7): All eligible patients received 60 mg furosemide, 150 mg placebo of aliskiren, and 300 mg placebo aliskiren once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Furosemide 60 mg + Aliskiren 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Period 2 (Day 8 to day 17): Patients received 60 mg furosemide, 150 mg aliskiren and 300 mg placebo once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Furosemide 60 mg + Aliskiren 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Period 3 (Day 18 to day 27): Patients received 60 mg furosemide, 300 mg aliskiren and 150 mg placebo of aliskiren once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren 150 mg</intervention_name>
    <description>Aliskiren 150 mg tablet</description>
    <arm_group_label>Furosemide 60 mg + Aliskiren 150 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide 60 mg</intervention_name>
    <description>Furosemide 60 mg commercially-available tablets</description>
    <arm_group_label>Furosemide 60 mg</arm_group_label>
    <arm_group_label>Furosemide 60 mg + Aliskiren 150 mg</arm_group_label>
    <arm_group_label>Furosemide 60 mg + Aliskiren 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Aliskiren</intervention_name>
    <description>Matching placebo for aliskiren 150 mg and 300 mg</description>
    <arm_group_label>Furosemide 60 mg</arm_group_label>
    <arm_group_label>Furosemide 60 mg + Aliskiren 150 mg</arm_group_label>
    <arm_group_label>Furosemide 60 mg + Aliskiren 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren 300 mg</intervention_name>
    <description>Aliskiren 300 mg tablet</description>
    <arm_group_label>Furosemide 60 mg + Aliskiren 300 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Systolic or diastolic heart failure, diagnosed with either NYHA functional class II to
             III at least 3 months prior to screening and on stable medication for at least 12
             weeks.

          -  Patients must have met either of the criteria at screening:

          -  Documented left ventricular ejection fraction (LVEF) greater than 20% but lower than
             40% OR

          -  Patients with a documented LVEF greater than 40% and with a history of NT-pro-BNP&gt;
             400pg/mL (or BNP &gt; 100pg/mL) within 12 months of screening.

        Exclusion Criteria:

          -  Treatment with Angiotensin Receptor Blockers (ARBs), aldosterone receptor antagonists
             and diuretics (other than furosemide) within 3 weeks of first dose and during the
             study. Beta blockers were permitted provided the dose was stable for at least 3 weeks
             before the first dose and remains so throughout the study.

          -  Hypertrophic cardiomyopathy (HCMP).

          -  If a subject is currently treated with furosemide, the dose must be stable for at
             least 3 weeks before the first dose and the dose must not exceed 60 mg daily

          -  Stable heart failure requiring treatment with both an ACE inhibitor and an ARB or
             Current acute decompensated heart failure.

          -  Mean sitting systolic blood pressure ≥160 mmHg and/or mean sitting diastolic blood
             pressure ≥ 100mmHg and/or secondary forms of hypertension.

          -  Persistent sitting systolic blood pressure &lt;90 mmHg.

          -  History of angioedema.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Lithuania</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2010</study_first_submitted>
  <study_first_submitted_qc>May 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2010</study_first_posted>
  <results_first_submitted>August 9, 2012</results_first_submitted>
  <results_first_submitted_qc>August 9, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 10, 2012</results_first_posted>
  <last_update_submitted>August 9, 2012</last_update_submitted>
  <last_update_submitted_qc>August 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure,</keyword>
  <keyword>aliskiren,</keyword>
  <keyword>furosemide,</keyword>
  <keyword>diuretic efficacy,</keyword>
  <keyword>interaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Furosemide (Fu) /Fu+Aliskiren(Alis)150mg/fu+Alis 300mg</title>
          <description>Treatment period 1 (Day 1 to Day 7): All eligible patients received 60 mg furosemide, 150 mg placebo of aliskiren, and 300 mg placebo aliskiren once daily.
Treatment Period 2 (Day 8 to day 17): Patients received 60 mg furosemide, 150 mg aliskiren and 300 mg placebo once daily.
Treatment Period 3 (Day 18 to day 27): Patients received 60 mg furosemide, 300 mg aliskiren and 150 mg placebo of aliskiren once daily.
Day 28, no study treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1 (Day 1 - Day 7)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37">Randomized and safety population</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 2 (Day 8 - Day 17)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Pharmacokinetic (PK) Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Pharmacodynamics (PD) Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period2(Day9-Day27) and Day 28</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Furosemide (Fu) /Fu+Aliskiren(Alis)150mg/fu+Alis 300mg</title>
          <description>Treatment period 1 (Day 1 to Day 7): All eligible patients received 60 mg furosemide, 150 mg placebo of aliskiren, and 300 mg placebo aliskiren once daily.
Treatment Period 2 (Day 8 to day 17): Patients received 60 mg furosemide, 150 mg aliskiren and 300 mg placebo once daily.
Treatment Period 3 (Day 18 to day 27): Patients received 60 mg furosemide, 300 mg aliskiren and 150 mg placebo of aliskiren once daily.
Day 28, no study treatment.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.6" spread="11.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Diuretic Efficacy Index 1 for Sodium Excretion</title>
        <description>Efficacy of furosemide for sodium excretion (efficacy index 1) was defined by dividing urinary sodium excretion by the urinary excretion of furosemide. Diuretic index 1 for sodium was calculated for the for the total 0 to 4 hour urine collection.</description>
        <time_frame>0 to 4 hours</time_frame>
        <population>All patients who received at least one dose of study drug and had evaluable pharmacodynamic (PD) data with no major protocol deviation in at least one period were included in the PD analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Furosemide 60 mg + Aliskiren Placebo</title>
            <description>Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7.</description>
          </group>
          <group group_id="O2">
            <title>Furosemide 60 mg+ Single Dose Aliskiren 150mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg on day 8.</description>
          </group>
          <group group_id="O3">
            <title>Furosemide 60 mg + Multiple Dose Aliskiren 150mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17).</description>
          </group>
          <group group_id="O4">
            <title>Furosemide 60 mg + Multiple Dose Aliskiren 300mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27).</description>
          </group>
        </group_list>
        <measure>
          <title>Diuretic Efficacy Index 1 for Sodium Excretion</title>
          <description>Efficacy of furosemide for sodium excretion (efficacy index 1) was defined by dividing urinary sodium excretion by the urinary excretion of furosemide. Diuretic index 1 for sodium was calculated for the for the total 0 to 4 hour urine collection.</description>
          <population>All patients who received at least one dose of study drug and had evaluable pharmacodynamic (PD) data with no major protocol deviation in at least one period were included in the PD analysis set.</population>
          <units>mmol/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.185" spread="4.4568"/>
                    <measurement group_id="O2" value="12.122" spread="6.2867"/>
                    <measurement group_id="O3" value="13.453" spread="8.3524"/>
                    <measurement group_id="O4" value="12.858" spread="6.1040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diuretic Efficacy Index 1 for Sodium Excretion</title>
        <description>Efficacy of furosemide for sodium excretion (efficacy index 1) was defined by dividing urinary sodium excretion by the urinary excretion of furosemide. Diuretic index 1 for sodium was calculated for the for the total 0 to 24 hour urine collection.</description>
        <time_frame>0 to 24 hours</time_frame>
        <population>All patients who received at least one dose of study drug and had evaluable pharmacodynamic (PD) data with no major protocol deviation in at least one period were included in the PD analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Furosemide 60 mg + Aliskiren Placebo</title>
            <description>Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7.</description>
          </group>
          <group group_id="O2">
            <title>Furosemide 60 mg+ Single Dose Aliskiren 150mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg on day 8.</description>
          </group>
          <group group_id="O3">
            <title>Furosemide 60 mg + Multiple Dose Aliskiren 150mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17).</description>
          </group>
          <group group_id="O4">
            <title>Furosemide 60 mg + Multiple Dose Aliskiren 300mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27).</description>
          </group>
        </group_list>
        <measure>
          <title>Diuretic Efficacy Index 1 for Sodium Excretion</title>
          <description>Efficacy of furosemide for sodium excretion (efficacy index 1) was defined by dividing urinary sodium excretion by the urinary excretion of furosemide. Diuretic index 1 for sodium was calculated for the for the total 0 to 24 hour urine collection.</description>
          <population>All patients who received at least one dose of study drug and had evaluable pharmacodynamic (PD) data with no major protocol deviation in at least one period were included in the PD analysis set.</population>
          <units>mmol/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.775" spread="5.2486"/>
                    <measurement group_id="O2" value="13.264" spread="6.3535"/>
                    <measurement group_id="O3" value="13.364" spread="6.1511"/>
                    <measurement group_id="O4" value="14.747" spread="6.3531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Pharmacokinetics (PK) of Furosemide: Area Under the Plasma Concentration-time Curve (AUC)</title>
        <description>Pharmacokinetic (PK) parameters were determined from the plasma concentration time profile of furosemide using a non-compartmental method:
AUCtau: Area under the plasma concentration-time curve from time zero to the end of the dosing interval
AUC (0-24): Area under the plasma concentration-time curve from time zero to 24 hours
AUClast: Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration. AUClast was calculated as the sum of linear trapezoids using non-compartmental analysis.
AUCinf: Area under the plasma concentration-time curve from time zero to infinity. AUCinf was calculated by adding AUClast and the value obtained from dividing the last measurable plasma concentration by λz, where λz was determined from automated linear regression of the last three time points with non-zero concentrations in the terminal phase of the log-transformed concentration-time profile</description>
        <time_frame>pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
        <population>All patients who received at least one dose of study drug and had evaluable Pharmacokinetic (PK) data with no major protocol deviation in at least one period were included in the PK analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Furosemide 60 mg + Aliskiren Placebo</title>
            <description>Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7.</description>
          </group>
          <group group_id="O2">
            <title>Furosemide 60 mg + Single Dose Aliskiren 150mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg on day 8.</description>
          </group>
          <group group_id="O3">
            <title>Furosemide 60 mg + Multiple Dose Aliskiren 150mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17).</description>
          </group>
          <group group_id="O4">
            <title>Furosemide 60 mg + Multiple Dose Aliskiren 300mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27).</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetics (PK) of Furosemide: Area Under the Plasma Concentration-time Curve (AUC)</title>
          <description>Pharmacokinetic (PK) parameters were determined from the plasma concentration time profile of furosemide using a non-compartmental method:
AUCtau: Area under the plasma concentration-time curve from time zero to the end of the dosing interval
AUC (0-24): Area under the plasma concentration-time curve from time zero to 24 hours
AUClast: Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration. AUClast was calculated as the sum of linear trapezoids using non-compartmental analysis.
AUCinf: Area under the plasma concentration-time curve from time zero to infinity. AUCinf was calculated by adding AUClast and the value obtained from dividing the last measurable plasma concentration by λz, where λz was determined from automated linear regression of the last three time points with non-zero concentrations in the terminal phase of the log-transformed concentration-time profile</description>
          <population>All patients who received at least one dose of study drug and had evaluable Pharmacokinetic (PK) data with no major protocol deviation in at least one period were included in the PK analysis set.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUCtau</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5217" spread="1996.7"/>
                    <measurement group_id="O2" value="4255" spread="1390.6"/>
                    <measurement group_id="O3" value="4638" spread="1532.9"/>
                    <measurement group_id="O4" value="4218" spread="1469.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5217" spread="1996.7"/>
                    <measurement group_id="O2" value="4255" spread="1390.6"/>
                    <measurement group_id="O3" value="4638" spread="1532.9"/>
                    <measurement group_id="O4" value="4218" spread="1469.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUClast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5154" spread="1999.2"/>
                    <measurement group_id="O2" value="4207" spread="1387.5"/>
                    <measurement group_id="O3" value="4535" spread="1531.6"/>
                    <measurement group_id="O4" value="4130" spread="1525.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUCinf</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5420" spread="2005.2"/>
                    <measurement group_id="O2" value="4559" spread="1387.4"/>
                    <measurement group_id="O3" value="4783" spread="1611.7"/>
                    <measurement group_id="O4" value="4381" spread="1578.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Pharmacokinetics (PK) of Furosemide: Observed Maximum Plasma Concentration Following Drug Administration at Steady State (Cmax, ss)</title>
        <description>Cmax,ss was directly determined from the raw plasma concentration-time data.</description>
        <time_frame>pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
        <population>All patients who received at least one dose of study drug and had evaluable pharmacokinetic (PK) data with no major protocol deviation in at least one period were included in the PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Furosemide 60 mg + Aliskiren Placebo</title>
            <description>Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7.</description>
          </group>
          <group group_id="O2">
            <title>Furosemide 60 mg + Single Dose Aliskiren 150mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg on day 8.</description>
          </group>
          <group group_id="O3">
            <title>Furosemide 60 mg + Multiple Dose Aliskiren 150mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17).</description>
          </group>
          <group group_id="O4">
            <title>Furosemide 60 mg + Multiple Dose Aliskiren 300mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27).</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetics (PK) of Furosemide: Observed Maximum Plasma Concentration Following Drug Administration at Steady State (Cmax, ss)</title>
          <description>Cmax,ss was directly determined from the raw plasma concentration-time data.</description>
          <population>All patients who received at least one dose of study drug and had evaluable pharmacokinetic (PK) data with no major protocol deviation in at least one period were included in the PK analysis set</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1702" spread="708.66"/>
                    <measurement group_id="O2" value="1326" spread="518.15"/>
                    <measurement group_id="O3" value="1317" spread="542.73"/>
                    <measurement group_id="O4" value="1180" spread="404.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Pharmacokinetics (PK) of Furosemide: Time to Reach the Maximum Concentration After Drug Administration (Tmax)</title>
        <description>Tmax was directly determined from the raw plasma concentration-time data.</description>
        <time_frame>pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
        <population>All patients who received at least one dose of study drug and had evaluable PK data with no major protocol deviation in at least one period were included in the PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Furosemide 60 mg + Aliskiren Placebo</title>
            <description>Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7.</description>
          </group>
          <group group_id="O2">
            <title>Furosemide 60 mg + Single Dose Aliskiren 150mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg on day 8.</description>
          </group>
          <group group_id="O3">
            <title>Furosemide 60 mg + Multiple Dose Aliskiren 150mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17).</description>
          </group>
          <group group_id="O4">
            <title>Furosemide 60 mg + Multiple Dose Aliskiren 300mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27).</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetics (PK) of Furosemide: Time to Reach the Maximum Concentration After Drug Administration (Tmax)</title>
          <description>Tmax was directly determined from the raw plasma concentration-time data.</description>
          <population>All patients who received at least one dose of study drug and had evaluable PK data with no major protocol deviation in at least one period were included in the PK analysis set</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.500" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O2" value="1.500" lower_limit="0.500" upper_limit="3.00"/>
                    <measurement group_id="O3" value="1.500" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O4" value="2.00" lower_limit="0.500" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Pharmacokinetics (PK) of Furosemide: Average Steady State Plasma Concentration During Multiple Dosing (Cav,ss)</title>
        <description>The average steady-state drug concentration in the plasma, blood, serum, or other body fluids during multiple dosing [amount x volume-1]. This was estimated as AUCτ/τ</description>
        <time_frame>pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours post dose</time_frame>
        <population>All subjects with evaluable pharmacokinetic parameter data with no exclusion flags and no major protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Furosemide 60 mg + Aliskiren Placebo</title>
            <description>Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7.</description>
          </group>
          <group group_id="O2">
            <title>Furosemide 60 mg + Single Dose Aliskiren 150mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg on day 8.</description>
          </group>
          <group group_id="O3">
            <title>Furosemide 60 mg + Multiple Dose Aliskiren 150mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17).</description>
          </group>
          <group group_id="O4">
            <title>Furosemide 60 mg + Multiple Dose Aliskiren 300mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27).</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetics (PK) of Furosemide: Average Steady State Plasma Concentration During Multiple Dosing (Cav,ss)</title>
          <description>The average steady-state drug concentration in the plasma, blood, serum, or other body fluids during multiple dosing [amount x volume-1]. This was estimated as AUCτ/τ</description>
          <population>All subjects with evaluable pharmacokinetic parameter data with no exclusion flags and no major protocol deviations.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217.4" spread="83.196"/>
                    <measurement group_id="O2" value="177.3" spread="57.942"/>
                    <measurement group_id="O3" value="193.2" spread="63.872"/>
                    <measurement group_id="O4" value="175.8" spread="61.219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Pharmacokinetics (PK) of Furosemide: Lowest Plasma Concentration Observed During a Dosing Interval at Steady State (Cmin, ss)</title>
        <description>The minimum observed steady-state drug concentration in the plasma, blood, serum, or other body fluids at the end of the dosing interval during multiple dosing [amount x volume-1]</description>
        <time_frame>pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 24 hours post dose</time_frame>
        <population>All patients who received at least one dose of study drug and had evaluable PK data with no major protocol deviation in at least one period were included in the PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Furosemide 60 mg + Aliskiren Placebo</title>
            <description>Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7.</description>
          </group>
          <group group_id="O2">
            <title>Furosemide 60 mg + Single Dose Aliskiren 150mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg on day 8.</description>
          </group>
          <group group_id="O3">
            <title>Furosemide 60 mg+ Multiple Dose Aliskiren 150mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17).</description>
          </group>
          <group group_id="O4">
            <title>Furosemide 60 mg + Multiple Dose Aliskiren 300mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27).</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetics (PK) of Furosemide: Lowest Plasma Concentration Observed During a Dosing Interval at Steady State (Cmin, ss)</title>
          <description>The minimum observed steady-state drug concentration in the plasma, blood, serum, or other body fluids at the end of the dosing interval during multiple dosing [amount x volume-1]</description>
          <population>All patients who received at least one dose of study drug and had evaluable PK data with no major protocol deviation in at least one period were included in the PK analysis set</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.42" spread="25.558"/>
                    <measurement group_id="O2" value="20.03" spread="23.780"/>
                    <measurement group_id="O3" value="19.80" spread="29.258"/>
                    <measurement group_id="O4" value="16.70" spread="20.868"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine Pharmacokinetics (PK) of Furosemide: Amount of Drug Excreted Into the Urine From Time Zero to 24 Hours After Administration (Ae0-24)</title>
        <description>The area under the plasma (or serum or blood) concentration-time curve from time zero to 24 h [mass × time × volume-1]</description>
        <time_frame>0 to 4, 4 to 8, 8 to 12 and 12 to 24 hours post dose</time_frame>
        <population>All patients who received at least one dose of study drug and had evaluable PK data with no major protocol deviation in at least one period were included in the PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Furosemide 60 mg + Aliskiren Placebo</title>
            <description>Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7.</description>
          </group>
          <group group_id="O2">
            <title>Furosemide 60 mg + Single Dose Aliskiren 150mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg on day 8.</description>
          </group>
          <group group_id="O3">
            <title>Furosemide 60 mg + Multiple Dose Aliskiren 150mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17).</description>
          </group>
          <group group_id="O4">
            <title>Furosemide 60 mg+ Multiple Dose Aliskiren 300mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27).</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Pharmacokinetics (PK) of Furosemide: Amount of Drug Excreted Into the Urine From Time Zero to 24 Hours After Administration (Ae0-24)</title>
          <description>The area under the plasma (or serum or blood) concentration-time curve from time zero to 24 h [mass × time × volume-1]</description>
          <population>All patients who received at least one dose of study drug and had evaluable PK data with no major protocol deviation in at least one period were included in the PK analysis set</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.61" spread="5.9012"/>
                    <measurement group_id="O2" value="15.08" spread="3.9613"/>
                    <measurement group_id="O3" value="14.98" spread="4.5264"/>
                    <measurement group_id="O4" value="13.63" spread="4.5134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine Pharmacokinetics (PK) of Furosemide: Renal Clearance (CLR)</title>
        <description>The renal clearance of drug [volume x time-1]</description>
        <time_frame>0 to 4, 4 to 8, 8 to 12 and 12 to 24 hours post dose</time_frame>
        <population>All patients who received at least one dose of study drug and had evaluable pharmacodynamic (PD) data with no major protocol deviation in at least one period were included in the PD analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Furosemide 60 mg + Aliskiren Placebo</title>
            <description>Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7.</description>
          </group>
          <group group_id="O2">
            <title>Furosemide 60 mg + Single Dose Aliskiren 150mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg on day 8.</description>
          </group>
          <group group_id="O3">
            <title>Furosemide 60 mg + Multiple Dose Aliskiren 150mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17).</description>
          </group>
          <group group_id="O4">
            <title>Furosemide 60 mg + Multiple Dose Aliskiren 300mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27).</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Pharmacokinetics (PK) of Furosemide: Renal Clearance (CLR)</title>
          <description>The renal clearance of drug [volume x time-1]</description>
          <population>All patients who received at least one dose of study drug and had evaluable pharmacodynamic (PD) data with no major protocol deviation in at least one period were included in the PD analysis set.</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.808" spread="1.3567"/>
                    <measurement group_id="O2" value="3.841" spread="1.4321"/>
                    <measurement group_id="O3" value="3.519" spread="1.3592"/>
                    <measurement group_id="O4" value="3.561" spread="1.4458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Creatinine Clearance</title>
        <description>Creatinine clearance= (Urine creatinine/Serum creatinine) x (Urine volume/(24*60)).</description>
        <time_frame>0 to 4, 4 to 8, 8 to 12 and 12 to 24 hours post dose</time_frame>
        <population>All patients who received at least one dose of study drug and had evaluable PD data with no major protocol deviation in at least one period were included in the PD analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Furosemide 60 mg + Aliskiren Placebo</title>
            <description>Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7.</description>
          </group>
          <group group_id="O2">
            <title>Furosemide 60 mg + Single Dose Aliskiren 150mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg on day 8.</description>
          </group>
          <group group_id="O3">
            <title>Furosemide 60 mg + Multiple Dose Aliskiren 150mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17).</description>
          </group>
          <group group_id="O4">
            <title>Furosemide 60 mg + Multiple Dose Aliskiren 300mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27).</description>
          </group>
        </group_list>
        <measure>
          <title>Creatinine Clearance</title>
          <description>Creatinine clearance= (Urine creatinine/Serum creatinine) x (Urine volume/(24*60)).</description>
          <population>All patients who received at least one dose of study drug and had evaluable PD data with no major protocol deviation in at least one period were included in the PD analysis set.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.745" spread="38.2884"/>
                    <measurement group_id="O2" value="109.657" spread="30.0667"/>
                    <measurement group_id="O3" value="103.841" spread="28.2845"/>
                    <measurement group_id="O4" value="105.304" spread="25.4076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine Sodium and Potassium Excretion Per Treatment at 4 Hours Postdose</title>
        <description>Urine was collected 4 hours postdose in all treatment groups for sodium and potassium analysis. Each patient was required to void their bladder before drug administration and at the end 4 hours.</description>
        <time_frame>4 hours postdose</time_frame>
        <population>All patients who received at least one dose of study drug and had evaluable pharmacodynamics (PD)data with no major protocol deviation in at least one period were included in the PD analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Furosemide 60 mg + Aliskiren Placebo</title>
            <description>Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7.</description>
          </group>
          <group group_id="O2">
            <title>Furosemide 60 mg + Single Dose Aliskiren 150mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg on day 8.</description>
          </group>
          <group group_id="O3">
            <title>Furosemide 60 mg + Multiple Dose Aliskiren 150mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17).</description>
          </group>
          <group group_id="O4">
            <title>Furosemide 60 mg + Multiple Dose Aliskiren 300mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27).</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Sodium and Potassium Excretion Per Treatment at 4 Hours Postdose</title>
          <description>Urine was collected 4 hours postdose in all treatment groups for sodium and potassium analysis. Each patient was required to void their bladder before drug administration and at the end 4 hours.</description>
          <population>All patients who received at least one dose of study drug and had evaluable pharmacodynamics (PD)data with no major protocol deviation in at least one period were included in the PD analysis set.</population>
          <units>mmol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sodium excretion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.992" spread="47.5976"/>
                    <measurement group_id="O2" value="104.031" spread="49.5036"/>
                    <measurement group_id="O3" value="98.691" spread="55.0495"/>
                    <measurement group_id="O4" value="93.341" spread="43.9419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium excretion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.555" spread="11.9749"/>
                    <measurement group_id="O2" value="19.403" spread="10.5975"/>
                    <measurement group_id="O3" value="23.046" spread="8.6829"/>
                    <measurement group_id="O4" value="21.037" spread="7.9355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine Sodium and Potassium Excretion Per Treatment at 8 Hours Postdose</title>
        <description>Urine was collected 8 hours postdose in all treatment groups for sodium and potassium analysis. Each patient was required to void their bladder before drug administration and at the end 8 hours.</description>
        <time_frame>8 hours postdose</time_frame>
        <population>All patients who received at least one dose of study drug and had evaluable pharmacodynamics (PD)data with no major protocol deviation in at least one period were included in the PD analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Furosemide 60 mg + Aliskiren Placebo</title>
            <description>Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7.</description>
          </group>
          <group group_id="O2">
            <title>Furosemide 60 mg + Single Dose Aliskiren 150mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg on day 8.</description>
          </group>
          <group group_id="O3">
            <title>Furosemide 60 mg + Multiple Dose Aliskiren 150mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17).</description>
          </group>
          <group group_id="O4">
            <title>Furosemide 60 mg + Multiple Dose Aliskiren 300mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27).</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Sodium and Potassium Excretion Per Treatment at 8 Hours Postdose</title>
          <description>Urine was collected 8 hours postdose in all treatment groups for sodium and potassium analysis. Each patient was required to void their bladder before drug administration and at the end 8 hours.</description>
          <population>All patients who received at least one dose of study drug and had evaluable pharmacodynamics (PD)data with no major protocol deviation in at least one period were included in the PD analysis set.</population>
          <units>mmol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sodium excretion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129.990" spread="49.2835"/>
                    <measurement group_id="O2" value="123.835" spread="56.2734"/>
                    <measurement group_id="O3" value="125.677" spread="58.6125"/>
                    <measurement group_id="O4" value="119.776" spread="59.0523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium excretion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.474" spread="12.2417"/>
                    <measurement group_id="O2" value="28.068" spread="12.5292"/>
                    <measurement group_id="O3" value="36.120" spread="14.4509"/>
                    <measurement group_id="O4" value="32.498" spread="9.6174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine Sodium and Potassium Excretion Per Treatment at 12 Hours Postdose</title>
        <description>Urine was collected 12 hours postdose in all treatment groups for sodium and potassium analysis. Each patient was required to void their bladder before drug administration and at the end 12 hours.</description>
        <time_frame>12 hours postdose</time_frame>
        <population>All patients who received at least one dose of study drug and had evaluable pharmacodynamics (PD)data with no major protocol deviation in at least one period were included in the PD analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Furosemide 60 mg + Aliskiren Placebo</title>
            <description>Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7.</description>
          </group>
          <group group_id="O2">
            <title>Furosemide 60 mg + Single Dose Aliskiren 150mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg on day 8.</description>
          </group>
          <group group_id="O3">
            <title>Furosemide 60 mg + Multiple Dose Aliskiren 150mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17).</description>
          </group>
          <group group_id="O4">
            <title>Furosemide 60 mg + Multiple Dose Aliskiren 300mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27).</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Sodium and Potassium Excretion Per Treatment at 12 Hours Postdose</title>
          <description>Urine was collected 12 hours postdose in all treatment groups for sodium and potassium analysis. Each patient was required to void their bladder before drug administration and at the end 12 hours.</description>
          <population>All patients who received at least one dose of study drug and had evaluable pharmacodynamics (PD)data with no major protocol deviation in at least one period were included in the PD analysis set.</population>
          <units>mmol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sodium excretion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151.254" spread="57.6190"/>
                    <measurement group_id="O2" value="142.476" spread="59.1617"/>
                    <measurement group_id="O3" value="144.839" spread="63.6708"/>
                    <measurement group_id="O4" value="140.887" spread="68.4341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium excretion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.013" spread="17.3416"/>
                    <measurement group_id="O2" value="37.827" spread="16.0087"/>
                    <measurement group_id="O3" value="46.770" spread="17.4395"/>
                    <measurement group_id="O4" value="44.137" spread="11.0631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine Sodium and Potassium Excretion Per Treatment at 24 Hours Postdose</title>
        <description>Urine was collected 24 hours postdose in all treatment groups for sodium and potassium analysis. Each patient was required to void their bladder before drug administration and at the end 24 hours.</description>
        <time_frame>24 hours postdose</time_frame>
        <population>All patients who received at least one dose of study drug and had evaluable pharmacodynamics (PD)data with no major protocol deviation in at least one period were included in the PD analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Furosemide 60 mg + Aliskiren Placebo</title>
            <description>Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7.</description>
          </group>
          <group group_id="O2">
            <title>Furosemide 60 mg + Single Dose Aliskiren 150mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg on day 8.</description>
          </group>
          <group group_id="O3">
            <title>Furosemide 60 mg + Multiple Dose Aliskiren 150mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17).</description>
          </group>
          <group group_id="O4">
            <title>Furosemide 60 mg + Multiple Dose Aliskiren 300mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27).</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Sodium and Potassium Excretion Per Treatment at 24 Hours Postdose</title>
          <description>Urine was collected 24 hours postdose in all treatment groups for sodium and potassium analysis. Each patient was required to void their bladder before drug administration and at the end 24 hours.</description>
          <population>All patients who received at least one dose of study drug and had evaluable pharmacodynamics (PD)data with no major protocol deviation in at least one period were included in the PD analysis set.</population>
          <units>mmol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sodium excretion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185.426" spread="69.9537"/>
                    <measurement group_id="O2" value="187.256" spread="69.1028"/>
                    <measurement group_id="O3" value="188.886" spread="73.8708"/>
                    <measurement group_id="O4" value="192.176" spread="76.0983"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium excretion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.323" spread="20.0607"/>
                    <measurement group_id="O2" value="53.107" spread="21.3416"/>
                    <measurement group_id="O3" value="62.715" spread="20.4014"/>
                    <measurement group_id="O4" value="61.012" spread="13.6072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Sitting Systolic Blood Pressure (msSBP)and Mean Sitting Diastolic Blood Pressure (msDBP)</title>
        <description>Sitting blood pressure was measured three times at 1 to 2-minute intervals. The mean of the three sitting blood pressure measurements was used as the average of the sitting office blood pressure. The msSBP and msDBP data were analyzed using a mixed effect model with fixed effects from treatment and treatment*time; random effect from patients and predose as covariate.</description>
        <time_frame>0.5 hour pre-dose, 0.5, 1, 2, 4, 8, 12 and 24 hours post dose.</time_frame>
        <population>Safety analysis set include subjects that received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Furosemide 60 mg + Aliskiren Placebo</title>
            <description>Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7.</description>
          </group>
          <group group_id="O2">
            <title>Furosemide 60 mg + Multiple Dose Aliskiren 150mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17).</description>
          </group>
          <group group_id="O3">
            <title>Furosemide go mg + Multiple Dose Aliskiren 300mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Sitting Systolic Blood Pressure (msSBP)and Mean Sitting Diastolic Blood Pressure (msDBP)</title>
          <description>Sitting blood pressure was measured three times at 1 to 2-minute intervals. The mean of the three sitting blood pressure measurements was used as the average of the sitting office blood pressure. The msSBP and msDBP data were analyzed using a mixed effect model with fixed effects from treatment and treatment*time; random effect from patients and predose as covariate.</description>
          <population>Safety analysis set include subjects that received study drug.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 predose (msSBP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.26" spread="1.62"/>
                    <measurement group_id="O2" value="117.09" spread="1.70"/>
                    <measurement group_id="O3" value="116.63" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 hour predose (msDBP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.70" spread="0.98"/>
                    <measurement group_id="O2" value="71.41" spread="1.04"/>
                    <measurement group_id="O3" value="71.39" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 hour Postdose (msSBP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.78" spread="1.64"/>
                    <measurement group_id="O2" value="113.19" spread="1.70"/>
                    <measurement group_id="O3" value="114.31" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 hour Postdose (msDBP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.94" spread="1.00"/>
                    <measurement group_id="O2" value="69.04" spread="1.04"/>
                    <measurement group_id="O3" value="69.86" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour Postdose (msSBP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.15" spread="1.64"/>
                    <measurement group_id="O2" value="112.22" spread="1.70"/>
                    <measurement group_id="O3" value="112.16" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour Postdose (msDBP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.22" spread="1.00"/>
                    <measurement group_id="O2" value="69.04" spread="1.04"/>
                    <measurement group_id="O3" value="68.96" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hour Postdose (msSBP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.61" spread="1.64"/>
                    <measurement group_id="O2" value="109.22" spread="1.70"/>
                    <measurement group_id="O3" value="109.63" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hour Postdose (msDBP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.39" spread="1.10"/>
                    <measurement group_id="O2" value="67.50" spread="1.04"/>
                    <measurement group_id="O3" value="68.39" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hour Postdose (msSBP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.50" spread="1.64"/>
                    <measurement group_id="O2" value="101.84" spread="1.70"/>
                    <measurement group_id="O3" value="101.06" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hour Postdose (msDBP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.85" spread="1.00"/>
                    <measurement group_id="O2" value="62.32" spread="1.04"/>
                    <measurement group_id="O3" value="59.07" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hour Postdose (msSBP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.75" spread="1.66"/>
                    <measurement group_id="O2" value="112.09" spread="1.70"/>
                    <measurement group_id="O3" value="109.95" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hour Postdose (msDBP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.33" spread="1.01"/>
                    <measurement group_id="O2" value="66.94" spread="1.04"/>
                    <measurement group_id="O3" value="66.46" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hour Postdose (msSBP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.99" spread="1.66"/>
                    <measurement group_id="O2" value="116.90" spread="1.70"/>
                    <measurement group_id="O3" value="115.16" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hour Postdose (msdBP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.86" spread="1.01"/>
                    <measurement group_id="O2" value="68.79" spread="1.04"/>
                    <measurement group_id="O3" value="68.50" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour Postdose (msSBP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.49" spread="1.66"/>
                    <measurement group_id="O2" value="116.69" spread="1.72"/>
                    <measurement group_id="O3" value="118.41" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hour Postdose (msDBP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.24" spread="1.01"/>
                    <measurement group_id="O2" value="71.66" spread="1.05"/>
                    <measurement group_id="O3" value="72.32" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diuretic Efficacy Index 2 for Water Excretion</title>
        <description>Efficacy of furosemide for water excretion (efficacy index 2) was defined by dividing urine volume by the urinary excretion of furosemide.Diuretic index 2 for water was calculated for the 0 to 4 hour fraction urine collection.</description>
        <time_frame>0 to 4 hours</time_frame>
        <population>All patients who received at least one dose of study drug and had evaluable PD data with no major protocol deviation in at least one period were included in the PD analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Furosemide 60 mg + Aliskiren Placebo</title>
            <description>Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7.</description>
          </group>
          <group group_id="O2">
            <title>Furosemide 60 mg + Single Dose Aliskiren 150mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg on day 8.</description>
          </group>
          <group group_id="O3">
            <title>Furosemide 60 mg + Multiple Dose Aliskiren 150mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17).</description>
          </group>
          <group group_id="O4">
            <title>Furosemide 60 mg + Multiple Dose Aliskiren 300mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27).</description>
          </group>
        </group_list>
        <measure>
          <title>Diuretic Efficacy Index 2 for Water Excretion</title>
          <description>Efficacy of furosemide for water excretion (efficacy index 2) was defined by dividing urine volume by the urinary excretion of furosemide.Diuretic index 2 for water was calculated for the 0 to 4 hour fraction urine collection.</description>
          <population>All patients who received at least one dose of study drug and had evaluable PD data with no major protocol deviation in at least one period were included in the PD analysis set.</population>
          <units>mL/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.402" spread="34.7866"/>
                    <measurement group_id="O2" value="109.773" spread="50.2433"/>
                    <measurement group_id="O3" value="119.239" spread="63.3655"/>
                    <measurement group_id="O4" value="122.157" spread="58.8815"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diuretic Efficacy Index 2 for Water Excretion</title>
        <description>Efficacy of furosemide for water excretion (efficacy index 2) was defined by dividing urine volume by the urinary excretion of furosemide.Diuretic index 2 for water was calculated for the 0 to 4 hour fraction and for the total 0 to 24 hour urine collection.</description>
        <time_frame>0 to 24 hours</time_frame>
        <population>All patients who received at least one dose of study drug and had evaluable PD data with no major protocol deviation in at least one period were included in the PD analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Furosemide 60 mg + Aliskiren Placebo</title>
            <description>Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7.</description>
          </group>
          <group group_id="O2">
            <title>Furosemide 60 mg + Single Dose Aliskiren 150mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg on day 8.</description>
          </group>
          <group group_id="O3">
            <title>Furosemide 60 mg + Multiple Dose Aliskiren 150mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17).</description>
          </group>
          <group group_id="O4">
            <title>Furosemide 60 mg + Multiple Dose Aliskiren 300mg</title>
            <description>Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27).</description>
          </group>
        </group_list>
        <measure>
          <title>Diuretic Efficacy Index 2 for Water Excretion</title>
          <description>Efficacy of furosemide for water excretion (efficacy index 2) was defined by dividing urine volume by the urinary excretion of furosemide.Diuretic index 2 for water was calculated for the 0 to 4 hour fraction and for the total 0 to 24 hour urine collection.</description>
          <population>All patients who received at least one dose of study drug and had evaluable PD data with no major protocol deviation in at least one period were included in the PD analysis set.</population>
          <units>mL/mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.439" spread="46.2607"/>
                    <measurement group_id="O2" value="151.859" spread="53.6734"/>
                    <measurement group_id="O3" value="154.116" spread="40.5598"/>
                    <measurement group_id="O4" value="175.112" spread="59.4236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>60 mg Furosemide + 150 mg Placebo + 300 mg Placebo</title>
          <description>60 mg furosemide + 150 mg placebo + 300 mg placebo</description>
        </group>
        <group group_id="E2">
          <title>60 mg Furosemide + 150 mg Aliskiren + 300 mg Placebo</title>
          <description>60 mg furosemide + 150 mg aliskiren + 300 mg placebo</description>
        </group>
        <group group_id="E3">
          <title>60 mg Furosemide + 300 mg Aliskiren + 150 mg Placebo</title>
          <description>60 mg furosemide + 300 mg aliskiren + 150 mg placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

